Review examined DNA methylation cancer tests already in clinical use
Tests using cancer-associated chemical marks on DNA were already in clinical practice when “DNA Methylation Cancer Biomarkers: Translation to the Clinic” was published in Front Genet on 14 November 2019. Locke WJ and colleagues reviewed how DNA methylation tests could inform cancer detection, treatment and monitoring. They examined tests on surgically removed tumors and DNA in bodily samples, as well as technical, regulatory and investment barriers to clinical use.
As cancer develops, DNA loses methylation across much of the genome while gaining it in particular regions, often around the beginnings of genes. Many of these changes happen early in tumor development and are widespread within a cancer type. That makes them useful candidates for early detection tests. Targeting only one or a few DNA locations can provide good coverage.
Tests on surgically removed tumor tissue can help identify indicators of treatment resistance and estimate likely outcomes. The review also described their use in classifying tumors by molecular characteristics and determining the tissue where a tumor originated. These applications give methylation testing a role after detection, when clinicians are assessing the cancer and its treatment.
Other tests examine cell-free DNA, genetic material found outside cells in blood, stool, urine and other bodily samples. The authors reported that cancer-associated methylation changes could be detected accurately in this DNA. They described the promise of economical, highly specific tests suitable for population-wide screening, with several examples already translated into clinical use. Tests on tumor DNA circulating in blood can also track treatment response, detect small amounts of cancer remaining after treatment and give an early indication of recurrence.
Bringing a test into practice involves more than detecting a cancer-associated mark. The review examined analytical performance, meaning how reliably a test measures its target, and whether the product meets its intended market's needs. It also considered factors affecting investment, including geography, and their implications for intellectual property and regulatory hurdles.